Ivan Hyep sold $808k of BCAX
Chief Financial Officer at Bicara Therapeutics Inc.. 28,000 shares at an average of $28.85, traded Jul 8, 2026, filed Jul 10, 2026.
Score components
- +22RoleCFO
- +22Trade size$808k at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000700, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | MOption exercise Common Stock10b5-1 | +12,500 | $3.79 | $47k | 157,855 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock10b5-1 | -22,757 | $28.60 | $651k | 135,098 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock10b5-1 | -4,413 | $29.82 | $132k | 130,685 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock10b5-1 | -830 | $30.31 | $25k | 129,855 | Jul 10, 2026 |
| Jul 8, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,592 | $0.00 | $0 | 58,992 | Jul 10, 2026 |
| Jul 8, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -908 | $0.00 | $0 | 38,836 | Jul 10, 2026 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 18Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $525k 18,750 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $280k 10,000 shares | -3% | |
| 17Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $350k 12,500 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $284k 10,000 shares | -3% | |
| 28Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $833k 28,750 shares | -14% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $188k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $301k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $254k 12,500 shares | -6% | |
| 6Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $126k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.